his study looked at the efficacy and adverse events in Enbrel (etanercept), Humira (dalimumab) & Stelara (ustekinumab).

Quote:

---

Background and objectives:
Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in ‘real-world’ patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in ‘real-world’ psoriasis patients treated with etanercept, adalimumab, and ustekinumab.

Patients and methods:
Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs.

Results:
In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI.

Conclusions:
Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.

Source: onlinelibrary.wiley.com

*Ealry view funding unknown

(Tue-28-02-2017, 11:57 AM)Fred Wrote: his study looked at the efficacy and adverse events in Enbrel (etanercept), Humira (dalimumab) & Stelara (ustekinumab).

Quote:

---

Background and objectives:
Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in ‘real-world’ patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in ‘real-world’ psoriasis patients treated with etanercept, adalimumab, and ustekinumab.

Patients and methods:
Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs.

Results:
In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI.

Conclusions:
Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.

Source: onlinelibrary.wiley.com

*Ealry view funding unknown

Isn't that a bit strange concerning eternacept? I read an article on an investigation in NL a comparison of eternacept and infliximab, and that showed that with eternacept, there exists no tendency to build up anti-bodies, which basically means that it can be used for a very long period, whithout having to stop using it.
The research was done at AMC hospital together with 5 other medical centres in NL.

Most of the failures are because of dosing. When the drug is prescribed for RA, there's room for variable dosing. Would be interesting to compare the two.